Innovation driven by
knowledge & science
Dedicated scientists and pharmacists expanding treatment options for physicians and patients.
Our focus areas
Our R&D centre brings together dedicated scientists and pharmacists focused on bioequivalence studies, patient-friendly dosage forms and the stability of therapeutic compounds, to expand treatment options for physicians and patients.
Formulation
Stable formulations with proven clinical efficacy, designed to be easier on the patient.
Stability
We test how a medicine behaves over time and under different storage conditions.
Bioequivalence
We prove our generics deliver the same effect as the reference medicine.
Patient-friendly forms
Easy-to-dose solutions and drops for children, and soft capsules that are easier to swallow.
Advanced analytics
Modern analytical techniques that ensure every result is precise.
From idea to pharmacy
- 01A clinical need
We start from what physicians and patients need.
- 02Formulation
Designing the formula and choosing the dosage form.
- 03Stability & bioequivalence
Proving quality and efficacy.
- 04Registration
Regulatory approval.
- 05Launch
The medicine reaches the pharmacy and the patient.
1stin the regionPansoft 500:
a regional first
In 2025 we launched Pansoft 500 mg, the first paracetamol soft gelatin capsule in Jordan and the Middle East. It is a direct result of our R&D centre’s work on patient-friendly dosage forms.
Read the innovation storyLet’s build a healthier
region together
Distributors, pharmacies, hospitals and healthcare partners: our business development team is ready to talk.